Business
Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors
-Forte Leadership is Significantly Strengthened with the Appointment of Dr. Scott Brun, M.D. to the Board of Directors DALLAS--(BUSINESS WIRE)-- Forte
About this update from Forte Biosciences, Inc.
[{"type":"text","content":"\n-Forte Leadership is Significantly Strengthened with the Appointment of Dr. Scott Brun, M.D. to the Board of Directors\n\n DALLAS--(BUSINESS WIRE)--\nForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors.\n\nDr. Brun is currently a Venture Partner at Abingworth and in addition to his consulting practice, he is also a Senior Advisor for Horizon Therapeutics, and a Senior Medical Advisor at Launch Therapeutics. Dr. Brun previously served in numerous executive capacities at AbbVie, most recently as Head of AbbVie Ventures. In Dr. Brun’s previous role as Head of Product Development at Abbvie, he led the global organization responsible for the development of AbbVie’s portfolio of early and late-stage clinical preregistration pipeline compounds as well as marketed compounds across a range of therapeutic areas. Dr Brun received his M.D. at The Johns Hopkins University School of Medicine.\n\nDr. Brun commented, “I am excited to join Paul as well as the Board and leadership team of Forte as they continue to drive forward with their development plans for FB-102 for a number of autoimmune disorders which currently have limited options available.”\n\n“We are extremely fortunate to have board members of Dr. Brun’s caliber join the team to help guide the pipeline development. We are all excited to work with Scott to help drive long term value for Forte,” said Forte’s chairman and CEO Paul Wagner, Ph.D.\n\nAbout Forte\n\nForte Biosciences, Inc. is a biopharmaceutical company and the lead product, FB-102, is a proprietary molecule with potentially broad autoimmune applications.\n\nForward Looking Statements\n\nForte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the Company’s current beliefs and expectations. Forward looking statements include statements regarding Forte’s beliefs, goals, intentions and ex...